ALX Oncology stockholders approve directors, pay, auditor
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026.
Rhea-AI Filing Summary
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026. Stockholders elected Class II directors Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. to serve until the 2029 annual meeting, each continuing until a successor is elected and qualified.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, as described in the proxy statement. In addition, they ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Daniel Curran, M.D.: 100,933,233 votes
Votes for Rekha Hemrajani: 82,732,430 votes
Votes for Chris Takimoto, M.D., Ph.D., F.A.C.P.: 100,946,696 votes
+4 more
7 metrics
Votes for Daniel Curran, M.D.
100,933,233 votes
Election of Class II director at June 10, 2026 annual meeting
Votes for Rekha Hemrajani
82,732,430 votes
Election of Class II director at June 10, 2026 annual meeting
Votes for Chris Takimoto, M.D., Ph.D., F.A.C.P.
100,946,696 votes
Election of Class II director at June 10, 2026 annual meeting
For votes on executive compensation
84,540,061 votes
Advisory vote on named executive officer compensation
Against votes on executive compensation
13,497,711 votes
Advisory vote on named executive officer compensation
Broker non-votes on executive compensation
18,313,833 votes
Advisory vote on named executive officer compensation
For votes on KPMG ratification
119,293,775 votes
Ratification of KPMG LLP as auditor for FY ending Dec. 31, 2026
Key Terms
broker non-votes, advisory vote, independent registered public accounting firm, Annual Meeting of stockholders, +1 more
5 terms
broker non-votes financial
"Broker Non-Votes --------------------------------------------------------------- | 84,540,061 | | | | 13,497,711 | | | | 2,953,259 | | | | 18,313,833 |"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory vote financial
"Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
independent registered public accounting firm financial
"The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Annual Meeting of stockholders financial
"ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026."
emerging growth company regulatory
"Emerging growth company Item 5.07 Submission of matters to a vote of security holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ALX Oncology (ALXO) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing three Class II directors, approving executive compensation on an advisory basis, and ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Which directors were elected at ALX Oncology (ALXO)’s June 10, 2026 annual meeting?
Stockholders elected Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P., as Class II directors, each to serve until the 2029 annual meeting of stockholders and until a successor is duly elected and qualified.
How did ALX Oncology (ALXO) stockholders vote on executive compensation in 2026?
Stockholders approved, on an advisory basis, the compensation of ALX Oncology’s named executive officers. The vote followed disclosures in the company’s proxy statement for the annual meeting, confirming support for the existing executive pay program.
Which audit firm did ALX Oncology (ALXO) stockholders ratify for fiscal 2026?
Stockholders ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026, confirming KPMG will continue auditing the company’s financial statements for that fiscal year.
What were the vote results for ALX Oncology (ALXO)’s director nominee Daniel Curran, M.D.?
Daniel Curran, M.D., received 100,933,233 votes for, 57,798 votes withheld, and 18,313,833 broker non-votes, resulting in his election as a Class II director to serve until the 2029 annual meeting of stockholders.
How many broker non-votes were recorded on ALX Oncology (ALXO)’s executive compensation proposal?
The advisory vote on named executive officer compensation recorded 18,313,833 broker non-votes, alongside the for, against, and abstain votes, reflecting shares not voted on this non-routine proposal by certain intermediaries.
AI-generated analysis. How Rhea-AI works. Not financial advice.
